Christopher P. Cannon, MD, a professor of medicine at Harvard Medical School and senior physician in the Cardiovascular Division at Brigham and Women’s Hospital, spoke about the benefit seen in a study of sotagliflozin for patients with acute heart failure.
Christopher P. Cannon, MD, was one of the investigators on the SOLOIST trial, which led to the approval of sotagliflozin, the first dual sodium-glucose cotransporter-1 and -2 (SGLT1/2) inhibitor. Cannon, a professor of medicine at Harvard Medical School and senior physician in the Cardiovascular Division at Brigham and Women’s Hospital, spoke about the benefit seen in the study for patients with acute heart failure.
Transcript
What is the extra benefit of the dual mechanism in the combined SGLT1/2 inhibitor? And what type of patient do you think would benefit the most and what type of patient would not gain any benefit from it?
Well, I think we don’t know, mechanistically, if this patient needs the dual vs the single. I think in clinical care, we always come back to the large clinical trials that had clinical benefit, and then try and use therapies in those type settings. And so for sotagliflozin in the SOLOIST trial, it was the first and largest of them to date, I think—although moderate size—to test this class in patients who had just had an acute heart failure exacerbation or worsening heart failure, and had a huge benefit.
So the number of patients you need to treat to prevent 1 from dying or being rehospitalized is 4, for 9 months, which is unheard of in terms of a benefit. Typically, you know, therapies are 30, 50, 100 patients to treat, to prevent 1 event. The absolute benefit seen in that acute heart failure setting is probably the first place that many of us will turn to use this to try and emulate what was seen in the in the SOLOIST trial. There are data with the other agents in smaller studies suggesting similar type benefits, but not sort of the magnitude that was seen so clearly in the SOLOIST trial overall.
Diagnostic Oversights Limit Luspatercept Benefits in MDS
May 8th 2024Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Coexistence of HIV, Hemophilia May Lead to Increased Presence of Coronary Artery Stenosis
May 8th 2024In patients living with HIV, the cardiovascular risk factors that come with infection may lead to an increased prevalence of coronary artery stenosis, especially in those who also have hemophilia.
Read More